DRKS00024062CompletedNot Applicable
Microvascular invasion of hepatocellular carcinoma predicts microvascular invasion of its recurrence.A potential implication for salvage liver transplantation
Allgemein-, Viszeral- u. Transplantationschirurgie Universitätsmedizin Mainz0 sites37 target enrollmentStarted: January 15, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 37
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 Years to 100 Years (—)
- Sex
- All
Inclusion Criteria
- •resectable hepatocellular carcinoma
Exclusion Criteria
- •distant metastases, incomplete resection
Investigators
Similar Trials
Recruiting
Phase 2
Hepatocellular carcinoma: vascular abnormalities prior to, during and following systemic anti-cancer treatment10019815liver cancerNL-OMON32482eids Universitair Medisch Centrum28
Active, not recruiting
Not Applicable
Hepatocellular carcinoma: vascular abnormalities prior to, during and following systemic anti-cancer treatment - everolimus and capecitabine for HCCEUCTR2008-003972-23-NLMC
Completed
Not Applicable
Non-invasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma by Blood-Oxygen-Level Dependent Magnetic Resonance Imaging (BOLD MRI)Hepatocellular CarcinomaNCT00963612University Health Network, Toronto80
Active, not recruiting
Phase 1
Hepatocellular carcinoma less than 3 cm treated with percutaneous tumour destruction: multicentric phase 2 trial assessing the impact of idarubicin-lipiodol intra-arterial chemotherapy on hepatic recurrence.The research hypothesis is that hepatic locoregional treatment with idarubicin and lipiodol would be an effective adjuvant therapy of hepatocellular carcinomaEUCTR2019-001362-15-FRniversity Hospital of Montpellier138
Recruiting
Not Applicable
Irresectable intrahepatic cholangiocellular carcinoma:Evaluation of the Efficacy of multimodal treatment by interstitial HDR-Brachytherapy combined with Gemcitabine/Cisplatin ChemotherapyC22.1Intrahepatic bile duct carcinomaDRKS00007161niversitätsklinikum Magdeburg50